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Abstract: Bronchopleural fistula (BPF) with prolonged air leak (PAL) is most often, though not always, a
sequela of lung resection. When this complication occurs post-operatively, it is associated with substantial
morbidity and mortality. Surgical closure of the defect is considered the definitive approach to controlling
the source of the leak, but many patients with this condition are suboptimal operative candidates. Therefore
there has been active interest for decades in the development of effective endoscopic management options.
Successful use of numerous bronchoscopic techniques has been reported in the literature largely in the form
of retrospective series and, at best, small prospective trials. In general, these modalities fall into one of two
broad categories: implantation of a device or administration of a chemical agent. Closure rates are high in
published reports, but the studies are limited by their small size and multiple sources of bias. The endoscopic
procedure currently undergoing the most systematic investigation is the placement of endobronchial valves.
The aim of this review is to present a concise discussion on the subject of PAL and summarize the described
bronchoscopic approaches to its management.
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Introduction
Prolonged air leak (PAL) is a dreaded post-operative
complication of thoracic surgery and a major clinical
problem in patients with pneumothorax of a medical
etiology. Although surgical management is considered the
definitive approach, bronchoscopic techniques have been
part of the toolkit for decades because many of these patients
are suboptimal surgical candidates. These endoscopic
interventions have evolved from crude occlusion devices
and primitive glues to sophisticated valves and resorbable
hemostatic sealants. The tools most widely used in current
practice can all be applied using flexible bronchoscopy.
Procedural success is typically defined as cessation (or
at least reduction) of air leak. Whether the chemical or
device route is chosen, published experience indicates that
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repeat procedures are common owing to incomplete initial
response. It should be recognized that the body of evidence
supporting bronchoscopic treatment of PAL is limited to,
at best, small prospective studies and is subject to numerous
forms of bias. When the largest series reporting results of
endoscopic interventions for post-pneumonectomy PAL
were systematically reviewed in 2007, an overall cure rate of
only 30% was obtained (1). An additional cautionary note is
that a systematic review of randomized controlled trials on
intra-operative sealant application for prevention of air leak
after lung cancer resectional surgery found that only a small
minority of these trials showed benefit and therefore firm
recommendations were withheld (2). This article begins
with an overview of important definitions and clinical
considerations pertaining to PAL followed by a discussion
of the individual bronchoscopic modalities.
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Definitions
Air leak into the pleural space originating either from an
airway or lung parenchyma is one of the most common
complications of thoracic procedures ranging from
transbronchial biopsy to pneumonectomy, in which case
the resultant pneumothorax is iatrogenic (3,4). Air leak
can also give rise to primary spontaneous pneumothorax
in patients with no grossly evident lung pathology as well
as secondary spontaneous pneumothorax (SSP) in those
with underlying pulmonary disease (e.g., emphysema, cystic
fibrosis, infection, etc.). Another etiology of air leak is chest
trauma. When the source of air entering the pleural space
is at the level of a segmental bronchus or more proximal,
the lesion is termed a bronchopleural fistula (BPF); a more
distal origin implies the presence of an alveolopleural
fistula (APF) (5). The preponderance of the literature on
the subject of air leak is of a surgical nature and therefore
post-operative BPF dominates the discourse, as it will in the
present review.
The presence of an air leak is indicated by the detection
of bubbles in the water seal chamber of the collection
system connected to the pleural drain. This is a common
phenomenon during the first 2 days after pulmonary
resection but persists beyond that only in a small minority
of patients (6). The severity of air leak is typically classified
according to the phase of the respiratory cycle during which
the bubbles appear, and it increases along the following
continuum: escape of air during forced exhalation maneuver
only (i.e., cough), during quiet exhalation only (spontaneous
breathing), during inspiration only (positive pressure
breathing), and during both inhalation and exhalation (7).
Drainage systems equipped with digital flow meters
capable of quantifying the leak are now also available (8).
Conventionally, an air leak is considered prolonged if it
persists beyond 5 days after the precipitating event. It is
the BPF complicated by PAL that poses the most serious
threat to the patient and the greatest clinical challenge.
Bronchoscopic interventions to be discussed herein are
best viewed in the context of this extreme of the disease
spectrum.
Epidemiology and clinical features
The most common cause of BPF is resectional thoracic
surgery, especially pneumonectomy (right more than left) (9)
and lung volume reduction surgery (LVRS) (10). The
reported incidence of post-resection BPF varies from
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as low as 2% (11) to as high as 90% (10) depending on
multiple variables such as type of operation and surgical
technique. Residual cancer at the resection margin (12)
and post-operative positive pressure ventilation (13) has
also been shown to increase the risk. Several patient factors
predisposing to the development of post-operative BPF
have been identified; notable among them are low forced
expiratory volume in 1 second (FEV1) (14), emphysema (15),
diabetes (16), chronic systemic steroid use (17), and
neoadjuvant chemotherapy and/or radiation (18). In the
immediate post-operative period, BPF implies stump
dehiscence and can present as an acute decompensation
related to the possibility of empyema, aspiration of pleural
space contents into one or both lungs, wasted ventilation,
and tension pneumothorax (19). Delayed (>30 days) postsurgical BPF is a more indolent illness characterized by
fever and constitutional symptoms reflective of chronic
reciprocal soilage of the pleural and alveolar spaces. Besides
its morbidity and attendant resource utilization, postresectional BPF is associated with a significant crude inhospital mortality rate, reported to be in excess of 70%
in one study (12). The basic tenets of the care of the BPF
patient are to ensure adequate ventilatory support, initiate
drainage of empyema if present, administer appropriate
antibiotics, and optimize nutritional status. The definitive
means of addressing a post-surgical BPF is operative
closure. Historically, bronchoscopic management of BPF
has been reserved for patients deemed to be poor candidates
for re-operation.
Localization
Pinpointing the site of post-resectional BPF is generally
straightforward as it is almost always located at the
bronchial stump. Localization of non-operative BPF and
APF can be more challenging. Chest computed tomography
is capable of identifying the location of a peripheral fistula
by demonstrating a communication between a bronchus
and the pleural space (20) (Figure 1). The detection of
bronchoscopically instilled methylene blue in the pleural
collection chamber would indicate the presence of a
fistula but would not establish its location. Retrograde
administration (i.e., from the pleural side), on the other
hand, can identify the culprit airway based on where the
dye is encountered at subsequent bronchoscopy (21). The
use of ventilation scintigraphy has also been described,
which is predicated on abnormal focal accumulation of
the inhaled tracer at the site of communication with the
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Figure 1 CT chest showing a communication between a peripheral
branch of the right middle lobe medial segment bronchus and the
pleural space (arrow) in a patient with a BPF due to erosive lung
cancer.

(SPECT) could enable more precise localization.
For the purpose of bronchoscopic intervention, realtime confirmation of the airway feeding the air leak is of
fundamental importance. Currently, the balloon occlusion
method described by Ratliff and colleagues in 1977 is the
most widely used approach (24). This technique involves
passing a Fogarty® balloon catheter (Edward Lifesciences
Corp., Irvine, CA, USA) through the instrument channel
of a flexible bronchoscope, which is then sequentially
inflated in the lobar bronchi. The cessation or significant
diminution of air leak following balloon occlusion of a
given lobar bronchus, which could take up to 2 minutes to
manifest, identifies it as leading to the fistula. The balloon
is then similarly inflated in the segmental bronchi and, if
feasible, the sub-segmental bronchi within the target lobe to
localize the culprit airway at those generations. Frequently,
more than one candidate bronchus will be identified. In
the case of endobronchial valve placement (see below), this
balloon occlusion test can be performed with an included
kit that allows for simultaneous sizing of the airway for
valve selection. Another option is the commercially
available Chartis® system (Pulmonx, Redwood City, CA,
USA) designed to assess for the presence of collateral
ventilation (25). This system provides a balloon catheter that
is equipped with a flow and pressure sensor. A persistently
negative pressure after inflation and elimination of air flow in
an airway indicates communication with a BPF.
Valves

Figure 2

99m

Tc-DTPA ventilation scintigraphy image showing

focal radiotracer accumulation in the lower left hemithorax (arrow)
corresponding to the site of PAL in a patient with left secondary
spontaneous pneumothorax in the setting of idiopathic pulmonary
fibrosis.

pleural space (Figure 2). Both radioisotope-labeled gas (e.g.,
133Xe and 81mKr) and aerosol have been employed for this
purpose (22). Inhalation of the latter, in the form of 99mTctagged diethylenetriamine pentaacetate (DTPA), was
performed to detect air leaks of various etiologies in a study
of 28 patients, which it did with an overall sensitivity of 78%
and a specificity of 100% (23). Fusion of scintigraphy with
concomitant single photon emission computed tomography
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Endobronchial valves (EBV) are currently the most actively
explored bronchoscopic modality for the management
of PAL. They were originally developed and studied as a
minimally invasive alternative to LVRS. EBVs are designed
to function as removable one-way barriers that permit air
and secretions to escape during exhalation but prevent air
from passing through during inhalation. When applied to
PAL, the hypothesis is that abolition by the EBV of airflow
through the airway leading to the fistula will allow the
defect to seal. Placement is envisioned to be temporary with
removal after a period of tissue healing. Fann and colleagues
inserted EBVs into the corresponding segmental bronchus
of each of six sheep following creation of an air leak due
to APF for which they first placed a pleural drain (26).
They were able to achieve rapid resolution of the air leak
in all animals. The first reported use of EBVs in humans
to control air leak was published by Snell and colleagues in
2005 after successful treatment of a patient with intractable
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Figure 3 Diagram of the Spiration® endobronchial valve. Image
courtesy of Olympus Respiratory.
Figure 5 Appearance of the Spiration® endobronchial valve in the
proximal right middle lobe bronchus as viewed from the bronchus
intermedius. Image courtesy of Dr. Kassem Harris.

Figure 4 Depiction of the Zephyr® endobronchial valve. Image
courtesy of Pulmonx, Inc.

pleuro-cutaneous fistula (27).
Two types of EBVs are currently produced in the United
States (US): the Emphasys Zephyr® Endobronchial Valve
System (Pulmonx, Redwood City, CA, USA) and the
Spiration® Valve System (Olympus Respiratory, Redmond,
WA, USA). Both are constructed on a Nitinol (nickeltitanium) frame. The body of the Spiration ® EBV is
umbrella-shaped and made of polyurethane (Figure 3),
whereas the Zephyr® EBV has a “duck bill” configuration
and is made of silicone (Figure 4). The Spiration® EBV
system comes in three different sizes corresponding to
airway diameters of 5, 6, and 7 mm. The Zephyr ® EBV
system is manufactured in size 4.0 and 5.5 for use in
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airways measuring 4–7 mm and 5.5–8.5 mm, respectively.
After the target airway is sized by means of the included
balloon kit, the corresponding EBV is deployed via a
flexible bronchoscope using the provided delivery catheter
(Figure 5). When appropriate, valve removal is accomplished
by grasping it with forceps passed through the instrument
channel and then pulling out the bronchoscope and forceps
together with the valve as one unit. As of this writing, only
the Spiration® product is approved by the US Food and
Drug Administration (FDA) and available exclusively under
the Humanitarian Device Exemption Program for postoperative PAL complicating lung resectional surgery.
In contrast to the other bronchoscopic interventions
covered in this review, the literature regarding EBV
placement for PAL includes not only a number of robust
retrospective series but also prospective observational data
(Table 1). The earliest series dates to 2009 and reports
the results of 40 cases of predominantly non-surgical
PAL managed with Zephyr® EBV insertion (28). The air
leak was abolished or reduced in 37/40 patients (92.5%),
allowing pleural drain discontinuation after a median of
7.5 days. A maximum of 9 valves was placed in any given
patient. In 8 of the 40 patients (20%), the valves were
subsequently removed without recurrence. Six patients
(15%) developed complications, among them valve
expectoration and malpositioning as well as pneumonia.
Subsequent smaller case series (29,33) reported similarly
high control rates with Spiration ® EBV in a population
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Table 1 Summary of the major studies of EBV insertion for PAL
Lead author,
year

Study design

Number
Valves/patient Procedural Time to pleural drain
of patients
Valve type (mean ± SD or success removalc (mean ± SD or
receiving EBVa
median)
rate (%)b
median days)

Valve retrieval Procedural
rate (% of complication
subjects)
rate (%)

Travaline
2009 (28)

Retrospective

40

Zephyr®

2.9±1.9

93

7.5

20

15

Gillespie
2011 (29)

Retrospective

7

Spiration®

3.5

75

16

71

0

Firlinger
2013 (30)

Prospective

13/19

Both

1.4±0.7

77

7.6±5

83

0

Dooms
2014 (31)

Prospective

9/10

Spiration®

4

67

4

100

0

Gilbert
2016 (32)

Retrospective

75/112

Spiration®

2

56d

4

NR

3

NR, not reported. a, total number of patients evaluated for EBV placement provided after slash where applicable; b, procedural success is
generally defined as rapid resolution and/or diminution of air leak following the intervention; c, time following EBV implantation; d, data not
available for all patients.

of mixed surgical and medical PALs, some of which were
refractory to prior operative interventions. A median of
approximately three valves per patient were implanted,
allowing pleural drain removal after about 2 weeks in cured
cases. No procedural adverse events were reported, and all
attempted valve extractions were successful. Dooms and
colleagues prospectively studied 10 patients with postresectional PAL, 9 of whom underwent treatment with a
median of 4 Spiration® EBV (31). Six of the 9 experienced
durable total or near total cessation of air leak while
the other 3 had recurrence, albeit at a lower flow rate,
attributable to valve displacement. Median time to chest
drain removal was 4 days, including the 3 non-responders
who were discharged with Heimlich valves and ultimately
had their drains discontinued at 14 days post-procedure.
All patients underwent uneventful valve removal and no
complications occurred that were attributable to the valves.
In an analogous prospective study, Firlinger and colleagues
used both EBV systems and were able to successfully
remove the pleural drains of 10 out of 13 patients (77%)
with PAL of mostly malignant and infectious etiology (30).
Most recently, Gilbert and colleagues compiled the
experience of multiple EBV centers consisting of 75
patients (out of a total of 112 evaluated for the procedure)
who received a median of 2.6 valves (32). The rate of air
leak resolution varied depending on cause of PAL: 100%
in those with iatrogenic injury versus 58% in the presence
of underlying lung disease (i.e., SSP). Overall median time
to cessation of air leak was 4 days, but that number was
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over 2 weeks in successful cases of SSP. Two patients (3%)
experienced complications deemed related to the valves,
namely empyema and contralateral pneumothorax.
Spigots
Bronchial occlusion with silicone for the treatment of BPF
was first reported over two decades ago (34). Subsequently,
Watanabe and colleagues developed endobronchial
Watanabe spigots (EWS ®, Novatech, Grasse, France)
made of silicone that they used to treat 60 patients with
air leak of various etiologies, in 58 of whom (97%) they
were able to achieve satisfactory positioning of the device.
Elimination or reduction of air leak was achieved in nearly
80% of cases (35). These spigots are coated with barium
sulfate for radiographic visibility; they have tapered ends
and come in three sizes (Figure 6). They are grasped with
forceps introduced through the working channel of the
bronchoscope and then advanced within the bronchus
until firmly wedged. The process is repeated if additional
bronchi need to be occluded. The spigots are later removed
when clinically feasible. Since the original publication
by Watanabe, several case series have documented the
successful use of EWS® in BPF management. The largest,
by Kaneda and colleagues, reported 21 patients who had
undergone endobronchial occlusion with a spigot (36).
Complete resolution of air leak after the initial procedure
was observed in 6/21 (29%) of patients while 12/21 (57%)
had reduction in air leak. The latter group required
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Figure 6 Three sizes of endobronchial Watanabe spigots (EWS®).
Image courtesy of Novatech.

additional spigots and/or pleurodesis to achieve complete
cessation of air leak. Recently, based on work with a canine
lung model, a new technique has been proposed for the
placement of EWS ® wherein a rotatable biopsy forceps
(FB-19CR-1, Olympus USA, Central Valley, PA, USA) is
used to grasp the spigot, which makes it more maneuverable
and easier to position (37). In Japan, the spigots are
an established and officially recognized device for the
management of intractable pneumothorax. They are not
listed as FDA-approved in the United States.
Chemical and thermal occlusion
Tissue adhesives
Cyanoacrylate compounds (e.g., n-butyl-2-cyanoacrylate
marketed as Histoacryl®, Tissue Seal, Ann Arbor, MI, USA)
are best known for their use in minor laceration repair and
surgical skin closure. In the 1980s, investigators instilled
this substance via a flexible bronchoscope into a canine
model of post-pneumonectomy BPF at the stump (38).
When the four study dogs were sacrificed and their tracheas
excised, the stumps were found to be sealed and covered by
a layer of scar tissue. An early series from Norway describes
successful closure of BPF with this compound following
pneumonectomy for lung cancer in two patients (39). More
recently, a group from Taiwan reported its use for a postlung transplant BPF (40). In all three cases administration
was through a flexible bronchoscope. Scappaticci et al.
published their experience after accumulating 20 cases of
BPF treated with instillation of cyanoacrylate (41). Almost
all were complications of lung resection for carcinoma
(18/20), and the majority (13/20) were small (<5 mm).
Overall, successful closure was achieved in 14/20 patients
(70%), predominantly when performed for small BPF
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(12/13). Chawla et al. applied this compound through
a flexible bronchoscope using a transbronchial needle
aspiration catheter for its delivery (42). They treated 9
patients, 4 of whom had non-surgical BPF. In those four
cases, balloon occlusion was employed to localize the origin
of the BPF. Durable closure occurred in 8 of the 9 patients
with the only failure being a post-pneumonectomy BPF
>8 mm in size. The pleural drain was removed a maximum
of 4 days following successful procedures except for a case
of tuberculous hydropneumothorax in which the drain
remained in place for 14 days. Those with experience
in endoscopic application of cyanoacrylates recommend
withdrawing the delivery catheter immediately upon
instillation to avoid gluing it to the airway tissue (43).
They likewise caution about keeping the bronchoscope
sufficiently far (i.e., at least 4 cm) from the catheter tip
during administration to avoid inadvertent gluing of the
instrument channel, which would require urgent rinsing
of the channel with a solvent such as acetone to restore its
patency (42).
Another substance in this category that has been
described for BPF management is the adhesive formed
by the combination of bovine serum albumin and
glutaraldehyde (BioGlue®, CryoLife, Kennesaw, GA, USA).
Two case series (44,45) include a total of four patients who
underwent instillation through either a flexible or rigid
bronchoscope, all achieving successful closure lasting as
long as 5 months post-procedure.
Hemostatic agents as sealants
The most documented agent for the bronchoscopic
treatment of BPF is fibrin glue (Tisseel®, Baxter, Deerfield,
IL, USA), which is indicated for surgical hemostasis and
bonding. Its effect is based on biological thrombogenesis
that occurs when the two components—fibrinogen
and thrombin—mix at the time of delivery. The fibrin
plug thus created is ultimately degraded by endogenous
plasmin, a process that is delayed for as long as 14 days by
the incorporation of a plasmin inhibitor called aprotinin
into the product (46). It is hoped that in the interim
tissue approximation will have taken place by secondary
intention. In a canine experiment conducted in the 1980s,
direct application of fibrin glue to an artificially created
APF significantly decreased the magnitude of air leak
compared to no intervention (47). Multiple case reports
(46,48) and series (49-51) describe the application of fibrin
glue in various amounts (typically 2–5 mL) through both
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Figure 7 Appearance of Coseal® upon instillation into a lobar
bronchus as it begins to congeal into a plug. Image courtesy of Dr.
Kassem Harris.

rigid and flexible bronchoscopes for the treatment of postoperative BPF. Of special interest is a review of 45 cases of
post-surgical BPF by Hollaus and colleagues, 29 of which
were managed with the introduction of fibrin glue via rigid
bronchoscopy (52). Their sample represents one of the
largest publications to date on the role of endoscopic BPF
closure. This approach was restricted to BPF smaller than
8 mm with no associated empyema, and the fibrin plug was
reinforced with spongy calf bone if the defect was greater
than 3 mm in size. Towards the end of the study period,
the procedure changed from endoluminal instillation
to submucosal injection of the glue. Of the 29 patients
treated endoscopically, 9 (31%) were cured and survived
to discharge free of pleural drains. Seven had successful
BPF closure (i.e., cessation of the air leak) but still required
permanent pleural drainage for chronic empyema. Another
7 experienced failure of the closure attempt. The remaining
6 patients died in hospital. The rate of initial successful
endoscopic BPF closure in this sample was therefore at least
16/29 or 55% depending on the response of the air leaks of
those who did not survive to discharge (not reported). The
authors note that eventual BPF recurrence was observed in
2 of the 16 cases discharged without an air leak (12%).
Coseal® (Baxter, Deerfield, IL, USA) is a polyethylene
glycol-based hydrogel that closes tissue defects by
crosslinking with native proteins. It is designed for leak
repairs during reconstructive vascular surgery and is fully
resorbed (Figure 7). Mehta and colleagues administered
this product to 22 patients with PALs, most of them
non-surgical, through the working channel of a flexible
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bronchoscope using a flexible catheter (53). Cessation of
air leak was achieved in 19 patients (86%) an average of
2 days after completing treatment, and the average time
to pleural drain removal was about 4 days. Three patients
expectorated the plug without complications, whereas one
required an emergent bronchoscopy to suction the plug
from the trachea after developing hypoxemia.
A number of physical hemostatic materials have also been
deployed through the flexible bronchoscope in individual
cases to successfully obliterate BPF. One example is the
insertion of strips cut from an absorbable sponge made from
purified porcine skin gelatin (Gelfoam®, Pfizer, New York,
NY, USA). Placement into two left upper lobe segmental
bronchi was accomplished by feeding the moistened strips
into the instrument channel with the aid of forceps and
then flushing them out with saline once the bronchoscope
was positioned in the desired location (54). In another
report, organized regenerated cellulose (Surgicel®, Ethicon,
Somerville, NJ, USA) was inserted in a similar fashion into
the left mainstem bronchus of a mechanically ventilated
patient whose BPF at that location was caused by an eroding
mass (55). To prevent dislodgment of the Surgicel® patch by
positive pressure ventilation, a Fogarty catheter was left in
place with the balloon inflated at the closure site to keep the
seal intact. Two days following the procedure, the patient
was breathing spontaneously and had no air leak even with
the balloon deflated. The catheter and pleural drains were
removed, and the patient was discharged 6 days after the
procedure.
Submucosal injections
In addition to the submucosal injection of fibrin glue
as performed by Hollaus et al. (see above), the other
substances that have been introduced through the flexible
bronchoscope into the submucosa at the site of a BPF fit one
of two categories: tissue expanders and sclerosing agents.
Experience with the former is limited to a description of
two cases in which a suspension of carbon-coated zirconium
beads in a water-based gel matrix (Durasphere®, Carbon
Medical Technologies, St. Paul, MN, USA) was injected
submucosally using a transbronchial aspiration needle (56).
In one of the two cases, subsequent cyanoacrylate instillation
was required to abolish a residual air leak. Over time,
Durasphere® is expected to promote collagen formation
that would add to its tissue bulking effect. This substance
is biocompatible but not biodegradable. The injection of
sclerosing agents such as tetracycline (57), silver nitrate
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Miscellaneous
Metallic non-valvular devices

Figure 8 An example of an Amplatzer occluder: AMPLATZER®
Duct Occluder II. Image courtesy of St. Jude Medical.

with (58) or without (59-61) an albumin suspension, pure
ethanol (62), and ethanolamine (63) appears to initially
produce BPF closure by causing local tissue edema,
which is followed by an inflammatory reaction and then
by granulation tissue that serves as the ultimate seal. Of
these chemicals, silver nitrate delivered through a flexible
bronchoscope is the best-described technique and has been
>80% effective in recent series (61).
Varoli and colleagues have published their results of
managing 35 post-resectional BPF with injections of
polidocanol (Aethoxysklerol ® , Kreussler, Wiesbaden,
Germany), a pharmaceutical designed for sclerotherapy to treat
spider and varicose veins (64). Successful closure was achieved
in 23/35 cases (66%), including post-pneumonectomy BPF as
large as 10 mm. Bronchoscopically injected ethanolamine, a
related compound, achieved cessation of air leak in 12/15 (80%)
predominantly medical patients.
Thermal therapy
Perhaps counterintuitively, the use of ablative energy
delivered through the flexible bronchoscope for the
management of BPF has also been described. The premise
is to induce tissue inflammation that will heal by forming
scar tissue that pulls the defect closed. While the use
of argon plasma coagulation is limited to a single case
report (65), Kiriyama and colleagues have published their
experience with Nd:YAG laser (power 5–20 W in 0.5-second
pulses) in 8 patients with post-surgical BPF, reporting
successful and durable closure in 4 of them (66).
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In this category, the most commonly employed item is
vascular embolization coils, described in case reports and
small series. Their insertion has been accompanied by the
concomitant instillation of either cyanoacrylate (67,68) or
fibrin glue (69,70). One of the most curious approaches to
endoscopic BPF management described in the literature
is the deployment of a lead split shot, otherwise known
as a fishing weight, using a flexible bronchoscope (24).
The scenario in which this technique was pioneered was
that of a patient with acute respiratory distress syndrome
complicated by barotrauma from positive pressure
ventilation. The plug was threaded onto a guidewire
positioned in the subsegmental bronchus identified as the
culprit airway beforehand. It was then pushed forward by
the tip of the bronchoscope following it along the guidewire
until it was wedged in place. After this 1977 report, there
have been no additional published articles documenting the
placement of lead shots for BPF.
Septal defect closure devices
Amplatzer™ occluders (AO) are well-known in the
field of cardiology for their use in septal defect closure,
an application from which they have been adapted for
management of BPF. They are made of Nitinol mesh with a
polyester fabric, a combination that provides initial coverage
and then promotes tissue growth over the device. There are
two types of such devices that have been used for BPF: the
AMPLATZER® Septal Occluder and the AMPLATZER®
Duct Occluder II (St. Jude Medical, St. Paul, MN, USA).
Both have a slim central waist with a disc on each end
(Figure 8). The appropriate size for a given BPF depends
on the dimensions of the stump and length of the fistula
to be treated. For placement, a guidewire is passed via the
instrument channel of a flexible bronchoscope and through
the BPF followed by a sheath. Next, the AO and its distal
disc are advanced past the fistula and positioned by pulling
back so that the disc sits flush against the opening. The
second disc is then delivered to the proximal side of the
defect. In the largest series, Fruchter and colleagues were
able to successfully close 9 of 11 (82%) mostly post-surgical
BPF in mainstem and lobar bronchi with AOs without
complications (71). The feasibility of this approach has since
been corroborated by others (72). AMPLATZER® vascular
plugs (St. Jude Medical, St. Paul, MN, USA), an analogous
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device functionally related to embolization coils, have also
been applied to BPF treatment by the same group (73).
These are likewise Nitinol-based, and the deployment
principle is similar to that of AOs.
Stents
Stents are the mainstay of bronchoscopic relief of central
airway obstruction. They have also been used for the
management of BPF as described in several case reports and
series. Metallic stents are known to incite an inflammatory
response that generates granulation tissue. When airway
patency is the goal, this would be considered an untoward
effect of stent placement, but when defect closure is desired,
such overgrowth can be advantageous. In some instances,
the shape of a stent has been modified to make it better
suited for coverage of a particular fistula. The largest
series by Cao and colleagues describes the use of a fully
covered metallic stent (SigmaMed Industrial Co., Ltd.,
Huaian, China; CZES type) in 9 patients with fistulae,
7 of which were bronchopleural (74). Resolution of air
leak was achieved in all 7, and only one patient required
a repeat procedure for a complication, namely stent
expectoration. In another review of 7 patients with large
post-pneumonectomy BPF, Dutau and colleagues deployed
custom-made fully covered, self-expandable metallic stents
(SILMET® conical stent, Novatech, La Ciotat, France) via
rigid bronchoscopy to treat the fistulae with an immediate
success rate of 100% (75). Pre-procedure measurements of
the area to be covered by the stent were taken so that the
midpoint of the customized stent would coincide with the
defect. The authors intentionally oversized the stents by
2mm in diameter to allow maximal apposition. Chae and
colleagues used a custom-designed metallic, fully covered
stent with its distal third constricted—giving it a “wine
glass” appearance—in order to allow the thin stem to fit in
the BPF tract (76). The distal end of stent (the base of the
“wine glass”) was positioned on the outside of the stump
in the post-pneumonectomy space while the proximal end
(the bowl of the “wine glass”) occupied the intact portion
of the mainstem bronchus. Bronchoscopic inspection
2 months after the procedure revealed complete closure of
the BPF. An important drawback of customized stenting is
the time required to obtain these devices, as this prolongs
hospitalization and delays therapeutic intervention.
Silicone stents have also been placed using rigid
bronchoscopy for the management of large postpneumonectomy BPF. For instance, a customized Y-shaped
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silicone stent successfully occluded a left mainstem bronchus
stump dehiscence after trimming the corresponding bronchial
limb, pushing a cuff link-shaped prosthesis (DJ-FistulaTM,
Bryan Corp., Woburn, MA) into the stent’s distal lumen, and
suturing it with silk (77). Additionally, the stent was reinforced
with Surgicel® and fibrin glue to prevent any residual leaks.
Ferraroli and colleagues were also able to place a modified
Dumon® Y stent (Tracheobronxane Y; Novatech SA, La
Ciotat Cede, France) in a patient with a 2 mm right mainstem
bronchus stump fistula. The stent’s right limb was occluded with
silicone material taken from the same stent (78).
Blood patch
The instillation of autologous blood (blood patch) through
a pleural drain for the successful management of PAL has
been reported in case series (79). This approach relies
both on the immediate sealing effect of clotted blood
and on the resultant pleural inflammation and symphysis.
Endoscopic, catheter-guided delivery of autologous blood
has also been described. Wiaterek and colleagues reported
a patient with necrotizing pneumonia complicated by
pneumothorax and PAL. Using flexible bronchoscopy and
forceps, several layers of a hemostatic agent were applied
first (Surgicel®, Ethicon, Piscataway, NJ, USA) followed
by instillation of 3 mL of autologous blood via a modified
Fogarty® balloon catheter, resulting in immediate cessation
of air leak (80). The pleural drain was removed after two
days. In a case series of nine emphysema patients with
PAL despite spigot placement (EWS®, Novatech, Grasse,
France), bronchoscopic instillation of autologous blood
plus thrombin was performed through a 2.45 mm catheter
(PW-1L-1 and PW-5L-1, Olympus, Tokyo, Japan) passed
into the gap between the spigot and the bronchial wall and
directed peripherally under fluoroscopic guidance (81). The
process was repeated if air leak persisted; the total amount
of blood administered in each case did not exceed 25 mL.
Air leak cessation was eventually achieved in 7/9 patients
(77%) with diminution in the remaining 2. However, in 3 of
the 7 successful cases, air leak was fully abolished only after
subsequent pleurodesis.
Conclusions
Bronchoscopic interventions for PAL represent an evolving
field within interventional pulmonology (Table 2). While
they have yet to supplant operative management as the gold
standard, particularly for larger defects, their place in the
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Table 2 Summary of the available non-valvular bronchoscopic approaches to PAL management described in case series of ≥5 patients. Data from
references (35,36,41,42,52,53,61,64,66,71,74,75,81)
Type of bronchoscopy

Predominant fistula
etiology

Number of series
[cumulative patients]

Representative success
rates (%)a

Spigots

Flexible

Non-surgical

2 [81]

78–86

Spigots + blood patch

Flexible

Emphysema

1 [9]

77

Amplatzer™ occluders

Flexible

Surgical

1 [10]

82

Rigid

Surgical

2 [14]

100

Flexible

Surgical

2 [29]

70–89

Rigid

Surgical

1 [29]

55

Flexible

Non-surgical

1 [22]

86

Polidocanol (Aethoxysclerol®)

Flexible

Surgical

1 [35]

66

Silver nitrate

Flexible

Surgical

1 [17]

94

Flexible

Surgical

1 [8]

50

Intervention
Devices

Metallic stents
Tissue adhesives
Cyanoacrylates
Hemostatic agents
Fibrin glue (Tisseel®)
®

Hydrogel (Coseal )
Submucosal injections

Thermal therapy
Nd:YAG laser
a

, percentages reflect rates of complete cessation of leak, except for spigots wherein leak reduction is also included among the successes.

armamentarium may change over time as currently available
techniques are refined and new ones are introduced. The
endoscopic approach holds great appeal because of its
relatively low invasiveness, which is of great value for the
PAL patient who is at high surgical risk. This procedural
category is sorely lacking comparative studies, but there
is reason to believe that registry data and multicenter
collaborations will help narrow the evidence gap in the nottoo-distant future.
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